NewslettersHepatic Cell News BST02 Receives FDA Fast Track Designation in Liver Cancer Management By lbeveridge - February 9, 2024 0 The FDA has granted fast track designation to the investigational T cell therapy BST02 as a treatment for patients with liver cancer, according to a press release from Biosyngen. [Cancer Network] Press Release